Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
A DEVICE used to treat central sleep apnoea (CSA) has been found to increase mortality in HF patients with reduced ejection fraction.
Martin Cowie, presenting results from the Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure and Reduced Ejection Fraction (SERVE-HF) at a Hot Line session yesterday, said ‘lives will be saved’ as a result of this ‘game-changer’ study, which was reported simultaneously in the New England Journal of Medicine.
Cowie, from Imperial College London, warned physicians not to treat HF patients with reduced EF and CSA with this device known as adaptive servo-ventilation therapy (ASV).
‘This study has changed our understanding of sleep-disordered breathing in systolic heart failure- the text books will have to be rewritten,’ said Cowie.
However, he did emphasise that the results from this study cannot be generalised to patients with preserved EF or obstructive sleep apnoea.
CSA, he explained, is caused by the brain failing to trigger breathing during sleep and is associated with poor prognosis as well as death in patients with HF. ASV uses a non-invasive ventilator to treat the apnoea by delivering servo-controlled inspiratory pressure support via a face mask in addition to expiratory positive airway pressure. Although algorithms employed by different ASV devices vary slightly, the principle of treatment is the same - that is, back-up rate ventilation with adaptive pressure support.
Small studies have suggested multiple beneficial effects of ASV on surrogate markers in HF patients with CSA. Improvements have been observed in LVEF, plasma BNP levels, quality of life and functional outcomes. Post-hoc data from the recent CANPAP trial suggested that continuous positive airway pressure therapy (CPAP) might improve mortality when CSA is controlled in HF patients with CSA and EF of 40% or less.
Cowie reported that the SERVE-HF trial aimed to investigate the effects of adding ASV to guideline-based medical management on survival and cardiovascular outcomes in patients with HF with reduced EF and predominant CSA. The study was conducted in 91 centres in 11 countries including Germany, France, UK and Australia.
A total of 1325 patients were randomly assigned to guideline-based medical treatment Continued on page 2 with ASV (n = 666) for a recommended five hours per night seven days a week, or guidelinebased medical treatment alone (n = 659).
The primary endpoint was time to first event of all-cause death, life-saving cardiovascular intervention or unplanned hospitalisation for worseningHF. Secondary endpoints included both all-cause and cardiovascular mortality. The median follow-up was 31 months.
The results showed a 54.1% event rate of the primary endpoint in the ASV group and 50.8% for the control group (HR 1.13; 95% CI 0.97-1.31; P=0.10). However, all-cause and cardiovascular mortality were significantly higher in the ASV group (HR 1.28; 95% CI 1.06-1.55; P=0.01) than in the control group (HR 1.34; 95% CI 1.09-1.65; P=0.006).
In the light of these results, said Cowie, manufacturers have now issued ‘a global safety notice’, and he warned that this therapy should not used in patients with central sleep apnoea and reduced ejection fraction HF.
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
© 2017 European Society of Cardiology. All rights reserved